Subtype
Malignant Vascular Neoplasm
CI-CAN-00001191Explore in graph →
36 active trials4 approved drugs4 evidence items
- NCIt
- C7390
Loading cancer entity…
Subtype
CI-CAN-00001191Explore in graph →
Clinical trials
193 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (21)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04577755 | Pomalidomide Treatment in Patients With Kaposi Sarcoma | active not recruiting | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04339738 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT03069378 |
| A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma |
| active not recruiting |
| Phase 2 |
| 41 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Jul 17, 2026 |
| clinicaltrials |
| NCT04668300 | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma(DOSa) | active not recruiting | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials